Clinic Roundup

Endo Pharmaceuticals Holdings Inc., of Chadds Ford, Pa., and Bioniche Life Sciences Inc., of Belleville, Ontario, said preliminary Phase III results from an interim analysis showed that Urocidin, its intravesical formulation of Mycobacterial cell wall-DNA complex, showed that the product was well tolerated. The overall one-year disease-free survival rate was 25 percent, breaking down to 35 percent for patients with only papillary tumors and 21 percent for patients with carcinoma in situ with or without papillary tumors. The study enrolled 129 patients.